Aadi Bioscience, Inc. (NASDAQ: AADI), a US-based commercial-stage biopharmaceutical company, announced on Monday that it has named Mohammad Hirmand, MD as its new director.

Dr Hirmand has over 20 years of biotechnology clinical development experience. He has held the position of executive vice president and chief medical officer for Turning Point Therapeutics. He is the co-founder of Avenzo Therapeutics. He has worked as chief medical officer of Peloton Therapeutics and in various roles at Medivation, Inc., including most recently as its chief medical officer. Dr Hirmand has also served in clinical development roles of increasing responsibility at Nuvelo, Inc. (now ARCA Biopharma), SuperGen, Inc. (now Astex Pharmaceuticals, Inc.), Tularik, Inc. (now part of Amgen), and Theravance Biopharma, Inc.

Caley Castelein, MD, Aadi board chairman, said, 'We welcome Mohammad to our board at an exciting time for Aadi, as we advance the development of FYARRO for unmet clinical needs beyond our approved indication of PEComa. Mohammad is a world-class clinical development leader in oncology and will be a great complement to our board and partner with our highly experienced team. Mohammad has been instrumental in the development of Medivation's Xtandi and Welireg (belzutifan), when at Peloton Therapeutics. Most recently, he led the development of Turning Point Therapeutics' clinical pipeline including the tyrosine kinase inhibitor repotrectinib prior to the company's acquisition by BMS. We look forward to working together and to his contributions as we drive toward continued growth and clinical expansion here at Aadi.'